This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tahir, S. A. Articles by Thompson, T. C. Search for Related Content PubMed PubMed Citation Articles by Tahir, S. A. Articles by Thompson, T. C.

Development of an Immunoassay for Serum Caveolin-1

A Novel Biomarker for Prostate Cancer¹

Scott Department of Urology [S. A. T., C. R., T. L. T., Y. G., A. F., T. C. T.], Houston VA Medical Center [T. L. T., T. C. T.], Department of Medicine [R. H., J. D. M.], Department of Pathology [G. A., T. M. W.], Department of Molecular and Cellular Biology [T. C. T.], and Department of Radiology [T. C. T.], Baylor College of Medicine, Houston, Texas 77030

Purpose: Caveolin-1 (cav-1), the major protein component of caveolae, plays an important role in multiple signaling pathways, molecular transport, and cellular proliferation and differentiation. The specific functions of cav-1/caveolae are highly cell and context dependent. We have previously shown that cav-1 expression is increased in metastatic human prostate cancer and that cav-1 cellular protein expression is predictive of recurrence of the disease after radical prostatectomy. Recently, we reported that cav-1 is secreted by androgen-insensitive prostate cancer cells, and we detected, by Western blotting, cav-1 in the high-density lipoprotein₃ fraction of serum specimens from patients with prostate cancer.

Experimental Design: Using rabbit polyclonal antibodies with specificity for cav-1, we developed a direct sandwich immunoassay for the determination of cav-1 in serum. A recombinant human cav-1 fusion protein was overexpressed and purified from 293 PE cells and used as a calibrator.

Results: The assay was highly specific and had a minimum detection limit of 0.017 ng/ml (mean + 3 SD of zero calibrator) and measuring range of up to 200 ng/ml. Intra-assay coefficient of variation was 2.29–6.74% and inter-assay coefficient of variation was 2.81–6.43% over the serum concentration tested 0.04–31.89 ng/ml. The recovery limit of cav-1 by the assay was 89.55–100.28%. The median serum cav-1 level in 102 prostate cancer patients with clinically localized disease (0.463 ng/ml) was significantly higher than 81 healthy control men (0.324 ng/ml; P = 0.0446, Mann-Whitney test) or 107 men with benign prostatic hyperplasia (0.172 ng/ml; P = 0.0317, Mann-Whitney test).

Conclusions: Our results indicate that serum cav-1 has the power to differentiate between prostate cancer and benign prostatic hyperplasia patients and the potential to be an important biomarker for prostate cancer. Additional studies to test the potential of serum cav-1 as a diagnostic and/or prognostic marker in prostate cancer are warranted.

This article has been cited by other articles:

				S. A. Tahir, G. Yang, A. A. Goltsov, M. Watanabe, K.-i. Tabata, J. Addai, E. M. A. Fattah, D. Kadmon, and T. C. Thompson Tumor Cell-Secreted Caveolin-1 Has Proangiogenic Activities in Prostate Cancer Cancer Res., February 1, 2008; 68(3): 731 - 739. [Abstract] [Full Text] [PDF]

				E. Burgermeister, X. Xing, C. Rocken, M. Juhasz, J. Chen, M. Hiber, K. Mair, M. Shatz, M. Liscovitch, R. M. Schmid, et al. Differential Expression and Function of Caveolin-1 in Human Gastric Cancer Progression Cancer Res., September 15, 2007; 67(18): 8519 - 8526. [Abstract] [Full Text] [PDF]

				S. A. Tahir, A. Frolov, T. G. Hayes, M. P. Mims, B. J. Miles, S. P. Lerner, T. M. Wheeler, G. Ayala, T. C. Thompson, and D. Kadmon Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort. Clin. Cancer Res., August 15, 2006; 12(16): 4872 - 4875. [Abstract] [Full Text] [PDF]

				W. J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women With Breast Cancer J. Clin. Oncol., November 1, 2005; 23(31): 7794 - 7803. [Abstract] [Full Text] [PDF]

				N. K. Ibrahim, B. Samuels, R. Page, D. Doval, K. M. Patel, S.C. Rao, M. K. Nair, P. Bhar, N. Desai, and G. N. Hortobagyi Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6019 - 6026. [Abstract] [Full Text] [PDF]

				L. Li, C. H. Ren, S. A. Tahir, C. Ren, and T. C. Thompson Caveolin-1 Maintains Activated Akt in Prostate Cancer Cells through Scaffolding Domain Binding Site Interactions with and Inhibition of Serine/Threonine Protein Phosphatases PP1 and PP2A Mol. Cell. Biol., December 15, 2003; 23(24): 9389 - 9404. [Abstract] [Full Text] [PDF]